arsenic trioxide has been researched along with Cancer of Pancreas in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Lin, L; Lin, X; Ou, G; Pan, L; Su, M; Tan, Y; Tian, Z | 1 |
| Aitbayev, C; Batyrbekov, K; Begimbetova, D; Burska, AN; Fazyl, F; Gulyayev, A; Khamijan, M; Kukanova, A; Makishev, A; Manekenova, K; Omarov, T; Saliev, T; Sarbassov, D; Spatayev, Z; Yermekbayeva, B | 1 |
| Chen, FX; Fan, H; Jiang, G; Li, K; Tang, X; Wang, H; Wang, X; Xu, C; Zhang, J; Zhou, Y | 1 |
| Liu, S; Liu, Z; Pang, Y | 1 |
| Brandt-Rauf, P; Cassai, N; Dinnen, RD; Fine, RL; Mao, Y; Nichols, G; Qiu, W; Slavkovich, VN; Su, GH | 1 |
| Gao, JK; Long, B; Su, JN; Wang, LX; Wang, ZW; Ye, XT; Yin, XY; Zhou, XX | 1 |
| Dong, J; Hao, J; Huang, C; Lan, C; Lang, M; Li, X; Ren, H; Wang, H; Wang, X; Yang, S; Yang, Y; Yu, M | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Adachi, M; Wang, W; Zhang, R; Zhou, J; Zhu, D | 1 |
| Liang, T; Sun, B; Sun, D; Xue, D; Zhang, W; Zhao, S | 1 |
| Adrian, TE; Ding, X; Li, X | 2 |
1 trial(s) available for arsenic trioxide and Cancer of Pancreas
| Article | Year |
|---|---|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
11 other study(ies) available for arsenic trioxide and Cancer of Pancreas
| Article | Year |
|---|---|
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Topics: Apoptosis; Arsenic Trioxide; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
The Oxidative Drug Combination for Suppressing KRAS G12D Inducible Tumour Growth.
Topics: Animals; Arsenic Trioxide; Ascorbic Acid; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Humans; Mice; Oxidation-Reduction; Oxidative Stress; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Azepines; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Identification of Key Potential Targets and Pathway for Arsenic Trioxide by Systemic Bioinformatics Analysis in Pancreatic Cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Computational Biology; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; Heterografts; Humans; Male; Mice; Necrosis; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Stem Cell Assay; Voltage-Dependent Anion Channels | 2013 |
Arsenic Trioxide Inhibits Cell Growth and Invasion via Down- Regulation of Skp2 in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Movement; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Oxides; Pancreatic Neoplasms; S-Phase Kinase-Associated Proteins; Signal Transduction; Tumor Cells, Cultured; Wound Healing | 2015 |
Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; Mustard Compounds; Oxidative Stress; Oxides; Pancreatic Neoplasms; Phenylpropionates; Promoter Regions, Genetic; Reactive Oxygen Species; RNA Interference; Signal Transduction; Time Factors; Transcriptional Activation; Transfection; Xenograft Model Antitumor Assays | 2016 |
A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Growth Inhibitors; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Sesquiterpenes; Xenograft Model Antitumor Assays | 2009 |
Effects of arsenic trioxide on the cerulein-induced AR42J cells and its gene regulation.
Topics: Amylases; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Ceruletide; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; L-Lactate Dehydrogenase; Oligonucleotide Array Sequence Analysis; Oxides; Pancreatic Neoplasms | 2009 |
Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 7; Caspase 9; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Enzyme Activation; GADD45 Proteins; Humans; Intracellular Signaling Peptides and Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxides; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Time Factors; Transcription Factor CHOP; Transcription Factors; Tumor Suppressor Proteins | 2003 |
Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Colonic Neoplasms; DNA Fragmentation; Enzyme Activation; Gene Expression Regulation; Genes, bcl-2; Growth Inhibitors; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Nuclear Proteins; Oxides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 2004 |